|
Match
|
Document |
Document Title |
|
|
8183219 |
Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
The invention provides novel combination therapies for treating neurodegenerative disease which comprise a) neurotrophic factors or suitable fragments thereof and b) agents capable of causing...
|
|
|
8183221 |
Suppression of SCN9A gene expression and/or function for the treatment of pain
Disclosed herein are methods, sequences and nucleic acid molecules used to treat pain. Specifically, the methods and sequences include locally administering molecules that suppress the expression...
|
|
|
8183222 |
Method to inhibit cell growth using oligonucleotides
Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more...
|
|
|
8183362 |
Method and medicament for inhibiting the expression of a given gene
The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using...
|
|
|
8178662 |
Isolated AEBP1 genomic polynucleotide fragments from chromosome 7 and their uses
The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD...
|
|
|
8178506 |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
|
|
|
8178505 |
Method of predicting and reducing risk of metastasis of breast cancer to lung
A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample...
|
|
|
8173615 |
TRPM-2 antisense therapy
It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be...
|
|
|
8173617 |
RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
|
|
|
8173796 |
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may...
|
|
|
8173149 |
Method for producing porous β-tricalcium phosphate granules
A porous β-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter ...
|
|
|
8173614 |
Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene...
|
|
|
8168601 |
Method of delivering RNA interference and uses thereof
The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment...
|
|
|
8168604 |
Antisense antiviral compounds and methods for treating a filovirus infection
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection....
|
|
|
8168605 |
Polymeric oligonucleotide prodrugs
Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed.
|
|
|
8168775 |
Compositions and methods for inhibiting expression of transthyretin
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
|
|
|
8168608 |
Promoter and plasmid system for genetic engineering
This invention provides a series of low-copy number plasmids comprising restriction endonuclease recognition sites useful for cloning at least three different genes or operons, each flanked by a...
|
|
|
8168600 |
Compositions and methods for topical delivery of oligonucleotides
The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to...
|
|
|
8168583 |
2-fluoronucleosides
2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and c...
|
|
|
8168201 |
Vaccines
The present invention relates to compositions for inducing immune responses, including an antigen and a promiscuous T-cell epitope. Also provided are methods of inducing immune responses in hosts,...
|
|
|
8168610 |
Bispecific oligonucleotide for the treatment of CNS malignancies
CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of...
|
|
|
7351579 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Circovirus sequences associated with piglet weight loss disease (PWD)
The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and...
|
|
|
6046032 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
ARF-P19, a novel regulator of the mammalian cell cycle
The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma...
|
|
|
6008200 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Immunomodulatory oligonucleotides
Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies...
|
|
|
5998385 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antisense oligonucleotide modulation of raf gene expression
Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'-O--CH2 CH2 OCH3)...
|
|
|
5891715 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Adenoviral vectors of canine origin
The present invention resides in use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence for the preparation of a pharmaceutical composition intended for the...
|
|
|
5691198 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
p16 expression constructs and their application in cancer therapy
A variety of genetic constructs are disclosed that will find both in vitro and in vivo use in the area of tumor biology and cancer therapy. In particular, expression constructs are provided that...
|